Epilepsy Market Research Report - Global Forecast till 2027

てんかん市場調査レポート:状態別(てんかん薬剤耐性/難治性てんかん、その他)、診断と治療別(診断と治療)、最終用途別(病院、クリニック、外来手術センター、診断センター、その他)-2027年までの予測

ID: MRFR/HC/6261-CR | February 2021 | Region: Global | 196 Pages         

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 20

3.2 Scope of the Study 20

3.3 Assumptions & Limitations 20

3.3.1 Assumptions 20

3.3.2 Limitations 20

3.4 Market Structure 21

4 Research Methodology

4.1 Research Process 23

4.2 Primary Research 24

4.3 Secondary Research 25

4.4 Market Size Estimation 26

4.5 Forecast Model 26

5 Market Dynamics

5.1 Introduction 28

5.2 Drivers 29

5.2.1 Rising prevalence of epilepsy amongst the geriatric population 29

5.2.2 Increasing cases of brain injuries due to road accidents 29

5.2.3 Rising neurological disorders 29

5.2.4 Increasing research funding in epilepsy 29

5.3 Restraints 30

5.3.1 Loss of patent protection for branded drugs 30

5.3.2 High costs associated with the treatment of epilepsy 30

5.4 Opportunities 30

5.4.1 Entering developing economies 30

6 Market Factor Analysis

6.1 Porter’s Five Forces Analysis 32

6.1.1 Bargaining Power of Suppliers 32

6.1.2 Bargaining Power of Buyers 33

6.1.3 Threat of New Entrants 33

6.1.4 Threat of Substitutes 33

6.1.5 Intensity of Rivalry 33

6.2 Supply Chain Analysis 34

6.2.1 R&D 34

6.2.2 Manufacturing 34

6.2.3 Distribution 34

6.2.4 Marketing & Sales 34

6.2.5 Post-Sales Monitoring 35

6.3 Investment Opportunities 35

6.4 Pricing Analysis 35

6.5 Demographic Analysis 36

7 Epilepsy Market, by Condition

7.1 Overview 39

7.1.1 Epilepsy Drug-Resistant/ Intractable Epilepsy 41

7.1.2 Others 41

8 Epilepsy Market, by Diagnosis & Treatment

8.1 Overview 43

8.1.1 Diagnosis & Treatment 45

9 Epilepsy Market, by End User

9.1 Overview 50

10 Global Epilepsy Market, by Region

10.1 Overview 56

10.2 Americas 59

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.1 North America 64

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.1.1 US 68

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.1.2 CANADA 72

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.2 Latin America 75

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.2.1 BRAZIL 79

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.2.2.2 REST OF LATIN AMERICA 83

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3 Europe 87

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.1 Western Europe 92

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.1.1 Germany 96

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.1.2 France 100

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.1.3 UK 103

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.2 Italy 107

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.3 Spain 110

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.4 Rest of Western Europe 114

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.3.5 Eastern Europe 117

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4 Asia-Pacific 121

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.1.1 Japan 126

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.1.2 China 130

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.2 India 134

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.3 Australia 137

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.4 South Korea 141

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.4.5 Rest of Asia-Pacific 144

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.5 Middle East & Africa 148

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.6 Middle East 153

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.6.1.1 Saudi Arabia 157

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.6.1.2 Rest of Middle East 160

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

10.6.2 Africa 164

Epilepsy Market, by Condition

Epilepsy Market, by Diagnosis & Treatment

Epilepsy Market, by End User

11 Competitive Landscape

11.1 Company Market Share Analysis 169

11.1.1 Introduction 169

12 Company Profile

12.1 LivaNova PLC 172

12.1.1 Company Overview 172

12.1.2 Financial Overview 172

12.1.3 Products/Services Offered 173

12.1.4 Key Development 173

12.1.5 SWOT Analysis 173

12.1.6 Key Strategies 173

12.2 GlaxoSmithKline PLC 174

12.2.1 Company Overview 174

12.2.2 Financial Overview 174

12.2.3 Products/Services Offered 174

12.2.4 Key Development 175

12.2.5 SWOT Analysis 175

12.2.6 Key Strategies 175

12.3 Eisai Co. Ltd 176

12.3.1 Company Overview 176

12.3.2 Financial Overview 176

12.3.3 Products/Services Offered 176

12.3.4 Key Development 177

12.3.5 SWOT Analysis 177

12.3.6 Key Strategies 177

12.4 Pfizer Inc 178

12.4.1 Company Overview 178

12.4.2 Financial Overview 178

12.4.3 Products/Services Offered 178

12.4.4 Key Developments 179

12.4.5 SWOT Analysis 179

12.4.6 Key Strategies 179

12.5 Medtronic PLC 180

12.5.1 Company Overview 180

12.5.2 Financial Overview 180

12.5.3 Products/Services Offered 181

12.5.4 Key Developments 181

12.5.5 SWOT Analysis 181

12.5.6 Key Strategies 181

12.6 UCB SA 182

12.6.1 Company Overview 182

12.6.2 Financial Overview 182

12.6.3 Products/Services Offered 183

12.6.4 Key Developments 183

12.6.5 SWOT Analysis 183

12.6.6 Key Strategies 183

12.7 NeuroPace Inc 184

12.7.1 Company Overview 184

12.7.2 Financial Overview 184

12.7.3 Products/Services Offered 184

12.7.4 Key Developments 184

12.7.5 SWOT Analysis 184

12.7.6 Key Strategies 184

12.8 GW Pharmaceuticals PLC 185

12.8.1 Company Overview 185

12.8.2 Financial Overview 185

12.8.3 Products/Services Offered 185

12.8.4 Key Developments 186

12.8.5 SWOT Analysis 186

12.8.6 Key Strategies 186

12.9 Novartis AG 187

12.9.1 Company Overview 187

12.9.2 Financial Overview 187

12.9.3 Products/Services Offered 187

12.9.4 Key Developments 188

12.9.5 SWOT Analysis 188

12.9.6 Key Strategies 188

12.10 Johnson & Johnson Services Inc. 189

12.10.1 Company Overview 189

12.10.2 Financial Overview 189

12.10.3 Products/Services Offered 189

12.10.4 Key Developments 190

12.10.5 SWOT Analysis 190

12.10.6 Key Strategies 190

12.11 Abbott Laboratories 191

12.11.1 Company Overview 191

12.11.2 Financial Overview 191

12.11.3 Products/Services Offered 191

12.11.4 Key Developments 192

12.11.5 SWOT Analysis 192

12.11.6 Key Strategies 192

13 Appendix

13.1 Discussion Blue Print 194

14 List of Tables

TABLE 1 MARKET SYNOPSIS 18

TABLE 2 PRIMARY INTERVIEWS 23

TABLE 3 GLOBAL EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 40

TABLE 4 GLOBAL EPILEPSY MARKET, FOR EPILEPSY DRUG-RESISTANT/ INTRACTABLE EPILEPSY, BY REGION 2020–2027 (USD MILLION) 41

TABLE 5 GLOBAL EPILEPSY MARKET, FOR OTHERS, BY REGION 2020–2027 (USD MILLION) 41

TABLE 6 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 45

TABLE 7 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY REGION, 2020-2027 (USD MILLION) 46

TABLE 8 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY REGION, 2020-2027 (USD MILLION) 46

TABLE 9 GLOBAL EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 47

TABLE 10 GLOBAL EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 47

TABLE 11 GLOBAL EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 48

TABLE 12 GLOBAL EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 48

TABLE 13 GLOBAL EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 51

TABLE 14 GLOBAL EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 52

TABLE 15 GLOBAL EPILEPSY MARKET, FOR HOSPITALS, BY REGION 2020–2027 (USD MILLION) 52

TABLE 16 GLOBAL EPILEPSY MARKET, FOR CLINICS (FAMILY PRACTITIONERS/ INTERNAL MEDICINE), BY REGION 2020–2027 (USD MILLION) 53

TABLE 17 GLOBAL EPILEPSY MARKET, FOR AMBULATORY SURGICAL CENTERS (OUTPATIENT CENTERS), BY REGION 2020–2027 (USD MILLION) 53

TABLE 18 GLOBAL EPILEPSY MARKET, FOR DIAGNOSTIC CENTERS, BY REGION 2020–2027 (USD MILLION) 54

TABLE 19 GLOBAL EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 57

TABLE 20 GLOBAL PREVALENCE OF EPILEPSY 2020-2027 57

TABLE 21 GLOBAL INCIDENCE OF EPILEPSY 2020-2027 57

TABLE 22 AMERICAS: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 60

TABLE 23 AMERICAS: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 60

TABLE 24 AMERICAS: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 60

TABLE 25 AMERICAS: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 61

TABLE 26 AMERICAS: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 61

TABLE 27 AMERICAS: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 62

TABLE 28 AMERICAS: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 62

TABLE 29 AMERICAS: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 63

TABLE 30 AMERICAS: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 63

TABLE 31 NORTH AMERICA: EPILEPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64

TABLE 32 NORTH AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 64

TABLE 33 NORTH AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 65

TABLE 34 NORTH AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 65

TABLE 35 NORTH AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 66

TABLE 36 NORTH AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 66

TABLE 37 NORTH AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 67

TABLE 38 NORTH AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 39 NORTH AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 68

TABLE 40 US: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 68

TABLE 41 US: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 42 US: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 43 US: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 70

TABLE 44 US: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 70

TABLE 45 US: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 71

TABLE 46 US: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 47 CANADA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 72

TABLE 48 CANADA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 72

TABLE 49 CANADA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 72

TABLE 50 CANADA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 51 CANADA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 52 CANADA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 74

TABLE 53 CANADA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 74

TABLE 54 CANADA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 55 LATIN AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 75

TABLE 56 LATIN AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 76

TABLE 57 LATIN AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 76

TABLE 58 LATIN AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 59 LATIN AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 78

TABLE 60 LATIN AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 78

TABLE 61 LATIN AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 79

TABLE 62 BRAZIL: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 79

TABLE 63 BRAZIL: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 79

TABLE 64 BRAZIL: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 80

TABLE 65 BRAZIL: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 80

TABLE 66 BRAZIL: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 67 BRAZIL: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 68 BRAZIL: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 69 REST OF LATIN AMERICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 83

TABLE 70 REST OF LATIN AMERICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 83

TABLE 71 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 83

TABLE 72 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 84

TABLE 73 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 84

TABLE 74 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 85

TABLE 75 REST OF LATIN AMERICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 85

TABLE 76 REST OF LATIN AMERICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 86

TABLE 77 EUROPE: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 88

TABLE 78 EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 88

TABLE 79 EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 88

TABLE 80 EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 89

TABLE 81 EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 89

TABLE 82 EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 90

TABLE 83 EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 90

TABLE 84 EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 91

TABLE 85 EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 91

TABLE 86 WESTERN EUROPE: EPILEPSY MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92

TABLE 87 WESTERN EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 93

TABLE 88 WESTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 93

TABLE 89 WESTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 93

TABLE 90 WESTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 94

TABLE 91 WESTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 94

TABLE 92 WESTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 95

TABLE 93 WESTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 95

TABLE 94 WESTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 96

TABLE 95 GERMANY: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 96

TABLE 96 GERMANY: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 97

TABLE 97 GERMANY: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 97

TABLE 98 GERMANY: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 98

TABLE 99 GERMANY: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 98

TABLE 100 GERMANY: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 99

TABLE 101 GERMANY: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 99

TABLE 102 FRANCE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 100

TABLE 103 FRANCE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 100

TABLE 104 FRANCE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 100

TABLE 105 FRANCE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 101

TABLE 106 FRANCE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 101

TABLE 107 FRANCE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 102

TABLE 108 FRANCE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 102

TABLE 109 FRANCE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 103

TABLE 110 UK: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 103

TABLE 111 UK: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 103

TABLE 112 UK: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 104

TABLE 113 UK: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 104

TABLE 114 UK: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 105

TABLE 115 UK: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 105

TABLE 116 UK: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 106

TABLE 117 UK: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 106

TABLE 118 ITALY: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 107

TABLE 119 ITALY: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 107

TABLE 120 ITALY: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 107

TABLE 121 ITALY: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 108

TABLE 122 ITALY: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 108

TABLE 123 ITALY: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 109

TABLE 124 ITALY: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 109

TABLE 125 ITALY: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 110

TABLE 126 SPAIN: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 110

TABLE 127 SPAIN: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 110

TABLE 128 SPAIN: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 111

TABLE 129 SPAIN: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 111

TABLE 130 SPAIN: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 112

TABLE 131 SPAIN: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 112

TABLE 132 SPAIN: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 113

TABLE 133 SPAIN: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 113

TABLE 134 REST OF WESTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 114

TABLE 135 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 114

TABLE 136 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 115

TABLE 137 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 115

TABLE 138 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 116

TABLE 139 REST OF WESTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 116

TABLE 140 REST OF WESTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 117

TABLE 141 EASTERN EUROPE: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 117

TABLE 142 EASTERN EUROPE: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 117

TABLE 143 EASTERN EUROPE: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 118

TABLE 144 EASTERN EUROPE: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 118

TABLE 145 EASTERN EUROPE: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 119

TABLE 146 EASTERN EUROPE: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 119

TABLE 147 EASTERN EUROPE: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 120

TABLE 148 EASTERN EUROPE: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 120

TABLE 149 ASIA-PACIFIC: ORPHAN DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122

TABLE 150 ASIA-PACIFIC: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 122

TABLE 151 ASIA-PACIFIC: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 123

TABLE 152 ASIA-PACIFIC: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 123

TABLE 153 ASIA-PACIFIC: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 124

TABLE 154 ASIA-PACIFIC: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 124

TABLE 155 ASIA-PACIFIC: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 125

TABLE 156 ASIA-PACIFIC: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 125

TABLE 157 ASIA-PACIFIC: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 126

TABLE 158 JAPAN: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 127

TABLE 159 JAPAN: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 127

TABLE 160 JAPAN: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 128

TABLE 161 JAPAN: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 128

TABLE 162 JAPAN: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 129

TABLE 163 JAPAN: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 129

TABLE 164 JAPAN: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 130

TABLE 165 CHINA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 130

TABLE 166 CHINA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 131

TABLE 167 CHINA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 131

TABLE 168 CHINA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 132

TABLE 169 CHINA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 132

TABLE 170 CHINA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 133

TABLE 171 CHINA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 133

TABLE 172 INDIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 134

TABLE 173 INDIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 134

TABLE 174 INDIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 134

TABLE 175 INDIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 135

TABLE 176 INDIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 135

TABLE 177 INDIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 136

TABLE 178 INDIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 136

TABLE 179 INDIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 137

TABLE 180 AUSTRALIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 137

TABLE 181 AUSTRALIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 137

TABLE 182 AUSTRALIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 138

TABLE 183 AUSTRALIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 138

TABLE 184 AUSTRALIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 139

TABLE 185 AUSTRALIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 139

TABLE 186 AUSTRALIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 140

TABLE 187 AUSTRALIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 140

TABLE 188 SOUTH KOREA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 141

TABLE 189 SOUTH KOREA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 141

TABLE 190 SOUTH KOREA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 141

TABLE 191 SOUTH KOREA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 142

TABLE 192 SOUTH KOREA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 142

TABLE 193 SOUTH KOREA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 143

TABLE 194 SOUTH KOREA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 143

TABLE 195 SOUTH KOREA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 144

TABLE 196 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 144

TABLE 197 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 144

TABLE 198 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 145

TABLE 199 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 145

TABLE 200 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 146

TABLE 201 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 146

TABLE 202 REST OF ASIA-PACIFIC: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 147

TABLE 203 REST OF ASIA-PACIFIC: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 147

TABLE 204 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY REGION, 2020–2027 (USD MILLION) 149

TABLE 205 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 149

TABLE 206 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 149

TABLE 207 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 150

TABLE 208 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 150

TABLE 209 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 151

TABLE 210 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 151

TABLE 211 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 152

TABLE 212 MIDDLE EAST AND AFRICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 152

TABLE 213 MIDDLE EAST: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 153

TABLE 214 MIDDLE EAST: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 153

TABLE 215 MIDDLE EAST: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 154

TABLE 216 MIDDLE EAST: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 154

TABLE 217 MIDDLE EAST: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 155

TABLE 218 MIDDLE EAST: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 155

TABLE 219 MIDDLE EAST: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 156

TABLE 220 MIDDLE EAST: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 156

TABLE 221 SAUDI ARABIA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 157

TABLE 222 SAUDI ARABIA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 157

TABLE 223 SAUDI ARABIA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 157

TABLE 224 SAUDI ARABIA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 158

TABLE 225 SAUDI ARABIA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 158

TABLE 226 SAUDI ARABIA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 159

TABLE 227 SAUDI ARABIA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 159

TABLE 228 SAUDI ARABIA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 160

TABLE 229 REST OF MIDDLE EAST: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 160

TABLE 230 REST OF MIDDLE EAST: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 160

TABLE 231 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 161

TABLE 232 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 161

TABLE 233 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 162

TABLE 234 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 162

TABLE 235 REST OF MIDDLE EAST: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 163

TABLE 236 REST OF MIDDLE EAST: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 163

TABLE 237 AFRICA: EPILEPSY MARKET, BY CONDITION, 2020–2027 (USD MILLION) 164

TABLE 238 AFRICA: EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 164

TABLE 239 AFRICA: EPILEPSY MARKET, FOR DIAGNOSIS, BY TYPE 2020–2027 (USD MILLION) 164

TABLE 240 AFRICA: EPILEPSY MARKET, FOR IMAGING DEVICES, BY TYPE 2020–2027 (USD MILLION) 165

TABLE 241 AFRICA: EPILEPSY MARKET, FOR TREATMENT, BY TYPE 2020–2027 (USD MILLION) 165

TABLE 242 AFRICA: EPILEPSY MARKET, FOR ANTI-EPILEPTIC DRUGS, BY TYPE 2020–2027 (USD MILLION) 166

TABLE 243 AFRICA: EPILEPSY MARKET, BY END USER, 2020–2027 (USD MILLION) 166

TABLE 244 AFRICA: EPILEPSY MARKET, FOR HOSPITALS, BY TYPE 2020–2027 (USD MILLION) 167


15 List of Figures

FIGURE 1 GLOBAL EPILEPSY MARKET: MARKET STRUCTURE 21

FIGURE 2 RESEARCH PROCESS 23

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 26

FIGURE 4 PORTER’S FIVE FORCES ANALYSIS OF THE GLOBAL EPILEPSY MARKET 32

FIGURE 5 SUPPLY CHAIN: EPILEPSY MARKET 34

FIGURE 6 GLOBAL EPILEPSY MARKET SHARE, BY CONDITION, 2020 (%) 39

FIGURE 7 GLOBAL EPILEPSY MARKET, BY CONDITION, 2020 & 2027 40

FIGURE 8 GLOBAL EPILEPSY MARKET SHARE, BY DIAGNOSIS & TREATMENT, 2020 (%) 44

FIGURE 9 GLOBAL EPILEPSY MARKET, BY DIAGNOSIS & TREATMENT, 2020 & 2027 45

FIGURE 10 GLOBAL EPILEPSY MARKET SHARE, BY END USER, 2020 (%) 50

FIGURE 11 GLOBAL EPILEPSY MARKET, BY END USER, 2020 & 2027 51

FIGURE 12 GLOBAL EPILEPSY MARKET, BY REGION, 2020 & 2027 (USD MILLION) 56

FIGURE 13 GLOBAL EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 58

FIGURE 14 AMERICAS: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 59

FIGURE 15 NORTH AMERICA: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 64

FIGURE 16 LATIN AMERICA: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 75

FIGURE 17 EUROPE: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 87

FIGURE 18 WESTERN EUROPE: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 92

FIGURE 19 ASIA-PACIFIC: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 121

FIGURE 20 MIDDLE EAST AND AFRICA: EPILEPSY MARKET SHARE, BY REGION, 2020 (%) 148

FIGURE 21 MIDDLE EAST: EPILEPSY MARKET SHARE, BY COUNTRY, 2020 (%) 153

FIGURE 22 GLOBAL EPILEPSY MARKET, MARKET SHARE ANALYSIS 2020 (%) 169

FIGURE 23 GLOBAL EPILEPSY MARKET COMPETITIVE LANDSCAPE 2020 (%) 170

てんかんマーケット

てんかん市場は2023年までに950億米ドルの評価額を獲得する予定であり、2020年から2027年の評価期間にわたって8.20%のCAGRを示しています

セグメンテーション

By Condition Epilepsy Drug Resistant/Intractable Epilepsy
By Diagnosis & Treatment Diagnosis Treatment
By End Use Hospitals Clinics Ambulatory Surgical Centers Diagnostic Centers

キープレーヤー

  • LivaNova PLC (U.K.)
  • GlaxoSmithKline PLC (U.K.)
  • Eisai Co. Ltd. (Japan)
  • Pfizer Inc. (U.S.)
  • Medtronic PLC (Ireland)
  • UCB SA (Belgium)
  • NeuroPace Inc. (U.S.)
  • GW Pharmaceuticals PLC (U.K.)
  • Novartis AG (Switzerland)
  • Johnson & Johnson Services Inc. (U.S.)

運転手

  • Increasing Incidence of PTE
  • The high sensitivity risk of elderly epilepsy is expected to fuel consumer demand
Speak to Analyst Request a Free Sample

てんかん市場の概要


MRFRによると、てんかん市場は2023年までに950億米ドルの評価額を獲得する予定であり、評価期間(2018-2023)にわたってCAGRは8.20%です。高齢者コミュニティにおけるてんかん有病率の増加と事故誘発性脳損傷症例の増加は、市場の成長を促進する主要な要因です。


新型コロナウイルス分析


新型コロナウイルスは比較的短期間で世界中に広がり、パンデミックになりました。罹患した患者の多くは、乾いた咳、疲労感、呼吸困難、発熱などの症状を示します。しかし、Covid-19の感染は、腎臓、肝臓、神経系を含む複数の組織を破壊します。Covid-19感染の一般的な神経学的症状には、せん妄、うつ病、発熱、嗅覚と味覚の喪失が含まれます。まれに脳卒中やてんかんを引き起こす可能性があります。これにより、効率的なてんかん治療と投薬に対する需要が高まっています。さらに、COVID 19治療に向けた研究開発投資の増加も、てんかん市場の成長に貢献する可能性があります。


マーケットダイナミクス


市場の成長を促進するPTEの発生率の増加


高齢者のてんかんの高感度リスクは、消費者の需要を刺激すると予想されます。さらに、心的外傷後てんかん(PTE)および心的外傷後発作(PTS)を引き起こす可能性のある脳損傷は、てんかん業界の需要を促進する可能性があります。てんかんに対する世界的な需要は、実験薬の開発、先進地域への新薬の到着、髄膜炎や腫瘍などの神経障害の有病率などの主要な要因によっててんかん市場にも影響されています。この上昇は、医療費の改善と可処分所得の増加によってさらに促進されています。


市場機会


早期診断のための高度なイメージング技術の採用の拡大が市場の成長に貢献


難治性てんかんの革新的な治療法の設計に焦点を当てた企業や、より効果的な医薬品を必要とする医師などの新たなトレンドは、てんかん市場への研究開発投資を増やしています。合理的ポリセラピーと早期診断のための高度な画像技術の採用も市場の成長に貢献しています。さらに、mHealthや遠隔医療などの高度なデジタルヘルスケアモデルの採用は、てんかん市場の成長機会を生み出す可能性があります。


市場制約


医薬品費の上昇は市場の成長を妨げる可能性が高い


一方、需要の拡大は、時間のかかる処方承認プロセスと薬費の上昇によって妨げられています。さらに、てんかんの課題に対する認識が低いことも、てんかん市場の成長を妨げる可能性があります。実際、消費者はますますゲーム会社やソーシャルメディアプラットフォームにてんかん警告を含めるよう請願しています。


セグメントの概要


この研究レポートは、てんかんの世界市場を障害、診断とケア、および最終用途別に分類しています。


[条件別]


状態によって、てんかん市場はてんかん薬剤耐性/難治性てんかんなどに分かれています。薬剤耐性てんかんセグメントは、予測期間の終わりまでに29億3,000万米ドルの価値に達すると予想されています。副作用を最小限に抑えて疾患を治療するための合理的なポリセラピーの出現は、てんかん市場にかなりの収益をもたらすと予想されます。


診断と治療によって


診断と治療によって、てんかんのてんかん市場は診断と治療に分けられます。この治療カテゴリーは、部分てんかん発作を治療するための安価な薬剤が入手可能であるため、予測期間中にてんかん市場を7.91パーセントのCAGRで牽引すると予想される。さらに、規制当局による成功した医薬品の承認は、このセグメントの発展を促進するでしょう。一方、診断セグメントは、評価期間にわたって8.76パーセントのCAGRで成熟すると予想されます。多数の画像検査と血液検査を使用して状態の早期診断を行うと、セグメントの開発が10倍に加速すると予想されます。


最終用途別


エンドユーザーに基づいて、てんかん市場は病院、診療所、診断センター、外来手術センターなどに分割されています。病院セグメントは、レビュー期間にわたって市場の成長を支配すると宣伝され、続いてクリニックセグメントが続きます。Moさらに, 病院の敷地からの医薬品の調達を奨励する病院は、市場を促進する可能性が高い.


地域分析


この地域のてんかん産業は、南北アメリカ、ヨーロッパ、アジア太平洋(APAC)、中東およびアフリカ(MEA)に分割されています。


北米は優れた医療インフラで市場を支配しています


その中で、南北アメリカは2017年のシェアの41%を占め、ヨーロッパ、APAC、MEAが中心となった。北米は、確立されたヘルスケア施設の利用可能性、ヘルスケアセクターの強化を目的とした有益な政府政策、および実質的な研究開発プログラムの存在により、市場への主要な貢献者です。


増加する研究開発投資がヨーロッパ市場を牽引


ヨーロッパのCAGRは、予測期間にわたって 8.31% になると予想されています。てんかんの治療に成功する医薬品の研究と生産への投資の増加は、この疾患の高い有病率と相まって、地域の需要を飛躍的に促進すると予想されます。


アジア太平洋地域の市場規模を拡大する新規医薬品の開発


APACてんかん市場は、国内で報告されている状態の発生率が高いため、2023年までに204万米ドルの価値に達する予定です。また、新製品の研究と生産のための実行可能な目的地として浮上しているインド、韓国、中国の国々は、予測期間にわたって消費者の需要を刺激するでしょう。


競争環境


有力企業が採用する主要な戦術となる効率的な医薬品の生産と製品承認の増加


てんかん治療業界で活動する企業は、政府機関による承認、パートナーシップ、世界中の各地域および地域の他のてんかん市場のリーダーとの戦略的合併および買収を通じて、グローバルなリーチを強化することを計画しています。てんかん治療の世界市場における地位を強化するために、堅固な進歩的な研究開発努力と製品パイプライン、および製品承認の拡大は、これらのプレーヤーが従う重要な戦略です。市場シェアを拡大するために、主要企業のほとんどは製品ポートフォリオの強化に取り組んでいます。新薬の発売は、抗てんかん薬の市場拡大を促進すると予測されています。


2020年12月:欧州のCNSスペシャリストがMedinutrix Ltdを買収し、アイルランドで最近買収した市場をリードするてんかん治療「Buccolam」の即時プラットフォームを提供しました。


キープレイヤー



  • LivanOva PLC (英国)

  • グラクソ・スミスクライン PLC (英国)

  • エーザイ株式会社 (日本)

  • ファイザー社 (米国)

  • メドトロニック PLC (アイルランド)

  • UCB SA (ベルギー)

  • NeuroPace Inc. (米国)

  • GW ファーマシューティカルズ PLC (英国)

  • ノバルティスAG (スイス)

  • ジョンソン・エンド・ジョンソン・サービス株式会社(米国)

  • アボット研究所 (米国)


最近の動向


2020年12月:新しいてんかん薬であるCenobamate(Xcopri)の試験で陽性の結果が示され、オープンラベル試験で発作の発生率が大幅に低下し、セノバメートを摂取した成人患者240人のうち、発作自由率は大幅に増加しました。患者による併用抗けいれん薬(ASM)の使用も制限されており、有効性にはほとんど影響しませんでした。


2020年12月:アラバマ大学バーミンガム校(UAB)により、LITTまたはレーザー間質性温熱療法と呼ばれる新しい低侵襲性てんかんレーザー手術が提案されました。特定の形態のてんかんでは、発作の原因となっている脳組織を破壊するためにレーザーを使用する新しい技術です。


レポート概要


このレポートは、世界のてんかん治療市場の成長に焦点を当てており、市場のさまざまなセグメントに関する詳細を含む市場のスナップショットを含む広範なエグゼクティブサマリーで構成されています。また、主要な参加者による地理的および市場シェア分析の観点からの市場競争力の概要を提供し、てんかん治療市場で出現している全体的な競争状況の詳細な分析を提供します。この調査はまた、その商品の世界市場に関する知識とデータ分析を提供します。



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 9.50 Billion
  CAGR   8.20% (2018-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Condition, Diagnosis & Treatment and End-use
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   LivaNova PLC (U.K.), GlaxoSmithKline PLC (U.K.), Eisai Co. Ltd. (Japan), Pfizer Inc. (U.S.), Medtronic PLC (Ireland), UCB SA (Belgium), NeuroPace Inc. (U.S.), GW Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Johnson & Johnson Services Inc. (U.S.), Abbott Laboratories (U.S.)
  Key Market Opportunities   Growing Adoption Of Advanced Imaging Technology For Early Diagnosis
  Key Market Drivers   Increasing Incidence of PTE to Drive Market Growth


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Epilepsy market is projected to grow at an 8.20% CAGR between 2020-2027.

The Americas is expected to dominate the epilepsy market.

Epilepsy market is predicted to touch USD 9,509.2 million by 2023.

Rising cases of brain injuries and prevalence of epilepsy among the older generation are the key factors driving the epilepsy market.

Hospitals will dominate the epilepsy market.